Rb10

Rb10 is a preclinical-stage synthetic peptide developed by Recepta Biopharma in collaboration with researchers from the Federal University of São Paulo (UNIFESP) and the University of São Paulo (USP). The drug is a complementarity-determining region (CDR)-derived peptide, specifically engineered from the sequence of a humanized monoclonal antibody. Rb10 is co-patented with Rb9, another CDR-derived peptide from ReceptaBio's pipeline. Preclinical studies have indicated that Rb10 possesses broad antitumor potential across multiple cancer types. While the specific molecular target is not publicly disclosed, CDR-derived peptides of this class typically function by mimicking the binding properties of the parent antibody or by directly inducing apoptosis and inhibiting signaling pathways in tumor cells.

Other names

Rb-10Rb10Rb 10